Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Vitamin A Palmitate to be registered as an active pharmaceutical ingredient for use in marketed formulations [1] Group 1 - The approved Vitamin A Palmitate is primarily used in fat-soluble vitamin injection solutions to supplement vitamins [1]

Core Viewpoint - The company Shihua Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Vitamin A Palmitate to be used as an active pharmaceutical ingredient in marketed formulations [1] Group 1 - The Vitamin A Palmitate is primarily used in fat-soluble vitamin injections to supplement vitamins [1]

Core Viewpoint - The company Shijiazhuang Pharmaceutical Group (stock code: 02005) has received approval from the National Medical Products Administration of China for its Vitamin A Palmitate to be registered as an active pharmaceutical ingredient for use in marketed formulations [1] Group 1 - The approved Vitamin A Palmitate is primarily used in lipid-soluble vitamin injections to supplement vitamins [1]

石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的維生素 A 棕櫚酸酯已獲中國國家藥品監督管理局批准登記成為在上市製劑使用的原 料藥。維生素 A 棕櫚酸酯主要用於脂溶性維生素注射液，補充維生素。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 香港，二零二五年十一月二十七日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 ...

Group 1 - The Indian Ministry of Finance has announced the imposition of anti-dumping duties on Vitamin A Palmitate imported from China, Switzerland, and the EU for a period of five years [1] - The specific anti-dumping duties are set at $14.95/kg for Shangyu NHU Bio-Chem Co., Ltd. from China, $20.87/kg for other Chinese producers, $0.87/kg for DSM Nutritional Products Limited from Switzerland, $8.2/kg for other Swiss producers, and $11.09/kg for EU producers [1] - The products affected include all forms of Vitamin A Palmitate with concentrations of 1.7 MIU/Gm and 1.0 MIU/Gm, excluding a specific concentration used for animals [1] Group 2 - The anti-dumping investigation was initiated following a request from Piramal Pharma Limited, an Indian domestic company, on March 28, 2024 [2] - The affirmative final ruling by the Indian Ministry of Commerce was made on March 10, 2025 [2]